[go: up one dir, main page]

PE20080214A1 - Moleculas de anticuerpo que se unen a la il-17 humana - Google Patents

Moleculas de anticuerpo que se unen a la il-17 humana

Info

Publication number
PE20080214A1
PE20080214A1 PE2007000825A PE2007000825A PE20080214A1 PE 20080214 A1 PE20080214 A1 PE 20080214A1 PE 2007000825 A PE2007000825 A PE 2007000825A PE 2007000825 A PE2007000825 A PE 2007000825A PE 20080214 A1 PE20080214 A1 PE 20080214A1
Authority
PE
Peru
Prior art keywords
cdr
seq
antibody
antibody molecules
refers
Prior art date
Application number
PE2007000825A
Other languages
English (en)
Inventor
Stephen Edward Rapecki
Andrew George Popplewell
Ralph Adams
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of PE20080214A1 publication Critical patent/PE20080214A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UN ANTICUERPO QUE INHIBE LA ACTIVIDAD DE LA INTERLEUQUINA 17 (IL-17) QUE COMPRENDE: A) UNA CADENA PESADA CUYO DOMINIO VARIABLE SE ENCUENTRA EN LA SEC ID Nº: 1 PARA CDR-H1, SEC ID Nº: 2 PARA CDR-H2 Y SEC ID Nº: 3 PARA CDR-H3; B) UNA CADENA LIGERA CUYO DOMINIO VARIABLE SE ENCUENTRA EN LA SEC ID Nº: 4 PARA CDR-L1, SEC ID Nº: 5 PARA CDR-L2 Y SEC ID Nº: 6 PARA CDR-L3. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION DEL ANTICUERPO. DICHO ANTICUERPO ES UTIL EN EL TRATAMIENTO DE ARTRITIS REUMATOIDE, ENFERMEDAD DE CROHN, PSORIASIS
PE2007000825A 2006-06-29 2007-06-26 Moleculas de anticuerpo que se unen a la il-17 humana PE20080214A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0612928.2A GB0612928D0 (en) 2006-06-29 2006-06-29 Biological products

Publications (1)

Publication Number Publication Date
PE20080214A1 true PE20080214A1 (es) 2008-04-08

Family

ID=36888319

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000825A PE20080214A1 (es) 2006-06-29 2007-06-26 Moleculas de anticuerpo que se unen a la il-17 humana

Country Status (14)

Country Link
US (2) US8057794B2 (es)
EP (1) EP2038305B1 (es)
JP (2) JP5693844B2 (es)
CN (1) CN101501072B (es)
AR (1) AR061538A1 (es)
BR (1) BRPI0713300A2 (es)
CA (1) CA2655874C (es)
CL (1) CL2007001840A1 (es)
EA (1) EA020113B1 (es)
ES (1) ES2614636T3 (es)
GB (1) GB0612928D0 (es)
PE (1) PE20080214A1 (es)
TW (1) TW200808829A (es)
WO (1) WO2008001063A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
AU2007284782B2 (en) 2006-08-11 2012-11-15 Merck Sharp & Dohme Corp. Antibodies to IL-17A
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
CN104628855A (zh) 2008-05-05 2015-05-20 诺维莫尼公司 抗il-17a/il-17f交叉反应性抗体及其使用方法
RU2539029C2 (ru) * 2008-09-29 2015-01-10 Роше Гликарт Аг Антитела против интерлейкина 17 (ил-17) человека и их применение
RU2015132478A (ru) * 2009-03-05 2015-12-10 Эббви Инк. Связывающие il-17 белки
CN104974250A (zh) 2009-05-05 2015-10-14 诺维莫尼公司 抗il-17f抗体及其使用方法
AU2010303166A1 (en) * 2009-10-10 2012-05-24 Eleven Biotherapeutics, Inc. IL-17 family cytokine compositions and uses
US8519107B2 (en) 2009-10-30 2013-08-27 Janssen Biotech, Inc. IL-17A antibodies
US20110293629A1 (en) 2010-05-14 2011-12-01 Bastid Jeremy Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists
MX2012013490A (es) 2010-05-20 2013-01-29 Ablynx Nv Materiales biologicos relacionados con her3.
US9328166B2 (en) * 2010-08-05 2016-05-03 Anaptysbio, Inc. Antibodies directed against IL-17
PT2654790T (pt) * 2010-12-22 2019-05-16 Teva Pharmaceuticals Australia Pty Ltd Anticorpo modificado com semivida melhorada
RS56298B1 (sr) 2011-01-14 2017-12-29 Ucb Biopharma Sprl Antitelo koje vezuje il-17a i il-17f
CN108220297A (zh) 2011-03-09 2018-06-29 细胞信号科技公司 用于生成单克隆抗体的方法和试剂
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
AU2012341081B2 (en) 2011-11-21 2015-06-04 Novartis Ag Methods of treating psoriatic arthritis (PsA) using IL-17 antagonists and PsA response or non- response alleles
JP2015519311A (ja) 2012-04-20 2015-07-09 ノバルティス アーゲー Ｉｌ−１７アンタゴニストを用いて強直性脊椎炎を治療する方法
WO2014107737A2 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Local delivery of il-17 inhibitors for treating ocular disease
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
EP4223312A1 (en) 2013-08-15 2023-08-09 Novartis AG Methods of treating plaque psoriasis using il-17 antagonists
RU2577228C2 (ru) * 2014-03-14 2016-03-10 Закрытое Акционерное Общество "Биокад" Анти-il-17-антитела, способ их получения и способ применения
RS65851B1 (sr) 2014-09-10 2024-09-30 Novartis Ag Upotreba antagonista il-17 za inhibiciju progresije strukturalnog oštećenja kod pacijenata sa psorijatičnim artritisom
CN108251431B (zh) 2015-03-05 2020-12-08 北京百特美博生物科技有限公司 双载体系统及其用途
WO2017160587A1 (en) 2016-03-16 2017-09-21 Abeome Corporation Neutralizing monoclonal antibodies to il-25 and uses thereof
CN107488227A (zh) * 2016-06-12 2017-12-19 三生国健药业（上海）股份有限公司 抗人白细胞介素‑17a单克隆抗体、其制备方法和应用
WO2017221174A1 (en) 2016-06-22 2017-12-28 Novartis Ag Methods of treating vitiligo using interleukin-17 (il-17) antibodies
EP3487881B1 (en) 2016-07-19 2024-08-21 Novartis AG Methods of treating new-onset plaque type psoriasis using il-17 antagonists
CN109715660A (zh) 2016-09-14 2019-05-03 北京韩美药品有限公司 一种能够特异性地结合il-17a的抗体及其功能片段
JP2019505516A (ja) 2016-11-28 2019-02-28 ノバルティス アーゲー インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
WO2018158741A1 (en) 2017-03-03 2018-09-07 Novartis Ag Psoriasis disease modification following long-term treatment with an il-17 antagonist
US10676522B2 (en) 2017-05-05 2020-06-09 Novartis Ag Methods of selectively treating asthma using IL-17 antagonists
US20210179702A1 (en) 2017-11-02 2021-06-17 Novartis Ag Method of treating tendinopathy using interleukin-17 (il-17)
US20200277369A1 (en) 2017-11-20 2020-09-03 Novartis Ag Method of treating hidradentitis suppurativa with il-17 antagonists
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
MA54857A (fr) 2019-01-31 2021-12-08 Numab Therapeutics AG Anticorps multispécifiques ayant une spécificité pour tnfa et il-17a, anticorps ciblant il-17a, et leurs procédés d'utilisation
TW202126329A (zh) 2019-09-20 2021-07-16 瑞士商諾華公司 使用白細胞介素－１７（ｉｌ－１７）拮抗劑治療自體免疫性疾病之方法
IL292926A (en) 2019-11-19 2022-07-01 Novartis Ag Methods of treating lupus nephritis using interleukin-17 (il-17) antagonists
WO2021111377A2 (en) 2019-12-06 2021-06-10 Novartis Ag Methods of treating lichen planus using interleukin-17 (il-17) antagonists
CN112300285B (zh) * 2020-11-06 2022-08-02 江苏荃信生物医药股份有限公司 一种定量检测血清中抗人白介素17单克隆抗体含量的酶联免疫分析方法
AU2023272370A1 (en) 2022-05-16 2025-01-02 Albert-Ludwigs-Universität Freiburg Methods of treating giant cell arteritis using interleukin-17 (il-17) antagonists
EP4525914A1 (en) 2022-05-18 2025-03-26 Novartis AG Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1053751A1 (en) 1999-05-17 2000-11-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions and methods for treating cell proliferation disorders
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
WO2005001044A2 (en) 2003-05-29 2005-01-06 Angiogenix, Inc. Compositions related to pleiotrophin methods and uses thereof
GB0312481D0 (en) * 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
ATE395083T1 (de) * 2003-11-21 2008-05-15 Ucb Pharma Sa Verfahren zur behandlung von multipler sklerose durch hemmung der il-17-aktivität
RU2346996C2 (ru) 2004-06-29 2009-02-20 ЮРОПИЭН НИКЕЛЬ ПиЭлСи Усовершенствованное выщелачивание основных металлов
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) * 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
WO2006073941A2 (en) 2004-12-31 2006-07-13 Genentech, Inc. Polypeptides that bind br3 and uses thereof
RU2007129263A (ru) 2005-02-14 2009-03-20 Вайет (Us) Антитела к интерлейкину-17f и другие антагонисты опосредуемой il-17f передачи сигналов и их применение
AU2006264212B2 (en) 2005-06-29 2010-10-28 Compumedics Limited Sensor assembly with conductive bridge
US7648976B2 (en) * 2005-11-23 2010-01-19 Bristol-Myers Squibb Company 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
LT2481753T (lt) * 2005-12-13 2018-05-25 Eli Lilly And Company Anti-il-17 antikūnai
EP1996622A2 (en) 2006-03-10 2008-12-03 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
AU2007284782B2 (en) 2006-08-11 2012-11-15 Merck Sharp & Dohme Corp. Antibodies to IL-17A
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products

Also Published As

Publication number Publication date
US20120129219A1 (en) 2012-05-24
JP2009540855A (ja) 2009-11-26
CN101501072A (zh) 2009-08-05
EA200900040A1 (ru) 2009-06-30
CN101501072B (zh) 2013-10-30
AR061538A1 (es) 2008-09-03
ES2614636T3 (es) 2017-06-01
CA2655874C (en) 2017-05-02
US8057794B2 (en) 2011-11-15
CA2655874A1 (en) 2008-01-03
TW200808829A (en) 2008-02-16
US8435761B2 (en) 2013-05-07
EP2038305A1 (en) 2009-03-25
BRPI0713300A2 (pt) 2012-04-17
JP2013252147A (ja) 2013-12-19
EA020113B1 (ru) 2014-08-29
JP5693844B2 (ja) 2015-04-01
GB0612928D0 (en) 2006-08-09
EP2038305B1 (en) 2016-11-16
CL2007001840A1 (es) 2008-01-18
WO2008001063A1 (en) 2008-01-03
US20100086538A1 (en) 2010-04-08

Similar Documents

Publication Publication Date Title
PE20080214A1 (es) Moleculas de anticuerpo que se unen a la il-17 humana
PE20120211A1 (es) Anticuerpos que tienen especificidad por ox40 humana
PE20070998A1 (es) Moleculas de anticuerpo que tienen especificidad para la il-6-humana
PE20121645A1 (es) Composiciones y metodos para tratar trastornos inflamatorios
PE20120343A1 (es) Anticuerpo anti-cmet que comprende una region bisagra
PE20211863A1 (es) Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap
PE20080181A1 (es) Anticuerpos que se unen al peptido beta-amiloide en el tratamiento de alzheimer
JP2018507220A5 (es)
RU2011129204A (ru) Антитела против ангиопоэтина-2 человека
PE20121579A1 (es) Proteinas de enlace al antigeno il-23 humanas
PE20130159A1 (es) Anticuerpos anti-cd40
PE20120622A1 (es) Anticuerpos anti-vegf y sus usos
PE20040947A1 (es) MOLECULAS DE ANTICUERPOS QUE TIENEN ESPECIFICIDAD PARA IL-1ß HUMANA
PE20170687A1 (es) Proteinas de enlace a cd127
PE20141547A1 (es) Anticuerpos neutralizantes frente a las exotoxinas principales tcda y tcdb de clostridium difficile
PE20061166A1 (es) Moleculas de anticuerpo que tienen especificidad para la il-17 humana
NZ596136A (en) Anti-cd100 antibodies and methods for using the same
AR080501A1 (es) Anticuerpos anti factor determinante antigenico de la muerte programada 1 (anti-pd1)
PE20120554A1 (es) Polipeptidos y metodo de tratamiento
PE20080980A1 (es) Anticuerpos anti-linfotoxina alfa
PE20212324A1 (es) Anticuerpos que reconocen tau
AR075925A1 (es) Anticuerpos anti-alfa5beta1 (alfa5beta1: glicoproteina integrina) y sus usos
PE20141564A1 (es) Moleculas de union para bcma y cd3
PE20120079A1 (es) Moleculas de anticuerpos mejoradas
PE20130214A1 (es) Composiciones y metodos para el diagnostico y tratamiento de tumores

Legal Events

Date Code Title Description
FC Refusal